Cryptococcus neoformans

Paradigm for the role of antibody immunity against fungi?

Liise-anne Pirofski, Arturo Casadevall

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Cryptococcus neoformans is an encapsulated fungus that is a frequent cause of life-threatening infections in patients with AIDS. C. neoformans has many similarities with encapsulated bacteria such as S. pneumoniae and H. influenzae for which antibody immunity is important in protection. However the role of antibody immunity in protection against C. neoformans has been controversial. Experiments with policlonal sera have produced conflicting evidence for and against the importance of antibody immunity in host defense. Experiments with monoclonal antibodies (mAb) to the C. neoformans capsular polysaccharide (CPS) have revealed the existence of protective, non- protective and disease-enhancing mAbs, suggesting that the divergent results obtained with polyclonal preparations may be a result of relative proportion of protective and non-protective antibodies in immune sera. Administration of protective mAbs can prolong survival, decrease organ fungal burden, and reduce serum polysaccharide antigen. In vitro experiments suggest that protective mAbs modify the course of infection by enhancing effector cell function against C. neoformans. Addition of mAb to antifungal drugs enhances their efficacy against C. neoformans in vivo and in vitro. Human-mouse chimeric antibodies with activity against C. neoformans have been constructed. A highly immunogenic capsular polysaccharide-protein vaccine has been synthesized that elicits protective antibodies in mice. Antibody immunity elicited by conjugate vaccines or provide by passive administration may be useful in the prevention treatment of human cryptococcal infections.

Original languageEnglish (US)
Pages (from-to)475-495
Number of pages21
JournalZentralblatt fur Bakteriologie
Volume284
Issue number4
StatePublished - Aug 1996

Fingerprint

Cryptococcus neoformans
Immunity
Fungi
Antibodies
Polysaccharides
Infection
Monoclonal Antibodies
Tissue Survival
Conjugate Vaccines
Serum
Human Influenza
Immune Sera
Pneumonia
Acquired Immunodeficiency Syndrome
Vaccines
Bacteria
Antigens
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Immunology

Cite this

Cryptococcus neoformans : Paradigm for the role of antibody immunity against fungi? / Pirofski, Liise-anne; Casadevall, Arturo.

In: Zentralblatt fur Bakteriologie, Vol. 284, No. 4, 08.1996, p. 475-495.

Research output: Contribution to journalArticle

@article{a45b4baf89fb431db6fc72a6a0f5def0,
title = "Cryptococcus neoformans: Paradigm for the role of antibody immunity against fungi?",
abstract = "Cryptococcus neoformans is an encapsulated fungus that is a frequent cause of life-threatening infections in patients with AIDS. C. neoformans has many similarities with encapsulated bacteria such as S. pneumoniae and H. influenzae for which antibody immunity is important in protection. However the role of antibody immunity in protection against C. neoformans has been controversial. Experiments with policlonal sera have produced conflicting evidence for and against the importance of antibody immunity in host defense. Experiments with monoclonal antibodies (mAb) to the C. neoformans capsular polysaccharide (CPS) have revealed the existence of protective, non- protective and disease-enhancing mAbs, suggesting that the divergent results obtained with polyclonal preparations may be a result of relative proportion of protective and non-protective antibodies in immune sera. Administration of protective mAbs can prolong survival, decrease organ fungal burden, and reduce serum polysaccharide antigen. In vitro experiments suggest that protective mAbs modify the course of infection by enhancing effector cell function against C. neoformans. Addition of mAb to antifungal drugs enhances their efficacy against C. neoformans in vivo and in vitro. Human-mouse chimeric antibodies with activity against C. neoformans have been constructed. A highly immunogenic capsular polysaccharide-protein vaccine has been synthesized that elicits protective antibodies in mice. Antibody immunity elicited by conjugate vaccines or provide by passive administration may be useful in the prevention treatment of human cryptococcal infections.",
author = "Liise-anne Pirofski and Arturo Casadevall",
year = "1996",
month = "8",
language = "English (US)",
volume = "284",
pages = "475--495",
journal = "International Journal of Medical Microbiology",
issn = "1438-4221",
publisher = "Urban und Fischer Verlag GmbH und Co. KG",
number = "4",

}

TY - JOUR

T1 - Cryptococcus neoformans

T2 - Paradigm for the role of antibody immunity against fungi?

AU - Pirofski, Liise-anne

AU - Casadevall, Arturo

PY - 1996/8

Y1 - 1996/8

N2 - Cryptococcus neoformans is an encapsulated fungus that is a frequent cause of life-threatening infections in patients with AIDS. C. neoformans has many similarities with encapsulated bacteria such as S. pneumoniae and H. influenzae for which antibody immunity is important in protection. However the role of antibody immunity in protection against C. neoformans has been controversial. Experiments with policlonal sera have produced conflicting evidence for and against the importance of antibody immunity in host defense. Experiments with monoclonal antibodies (mAb) to the C. neoformans capsular polysaccharide (CPS) have revealed the existence of protective, non- protective and disease-enhancing mAbs, suggesting that the divergent results obtained with polyclonal preparations may be a result of relative proportion of protective and non-protective antibodies in immune sera. Administration of protective mAbs can prolong survival, decrease organ fungal burden, and reduce serum polysaccharide antigen. In vitro experiments suggest that protective mAbs modify the course of infection by enhancing effector cell function against C. neoformans. Addition of mAb to antifungal drugs enhances their efficacy against C. neoformans in vivo and in vitro. Human-mouse chimeric antibodies with activity against C. neoformans have been constructed. A highly immunogenic capsular polysaccharide-protein vaccine has been synthesized that elicits protective antibodies in mice. Antibody immunity elicited by conjugate vaccines or provide by passive administration may be useful in the prevention treatment of human cryptococcal infections.

AB - Cryptococcus neoformans is an encapsulated fungus that is a frequent cause of life-threatening infections in patients with AIDS. C. neoformans has many similarities with encapsulated bacteria such as S. pneumoniae and H. influenzae for which antibody immunity is important in protection. However the role of antibody immunity in protection against C. neoformans has been controversial. Experiments with policlonal sera have produced conflicting evidence for and against the importance of antibody immunity in host defense. Experiments with monoclonal antibodies (mAb) to the C. neoformans capsular polysaccharide (CPS) have revealed the existence of protective, non- protective and disease-enhancing mAbs, suggesting that the divergent results obtained with polyclonal preparations may be a result of relative proportion of protective and non-protective antibodies in immune sera. Administration of protective mAbs can prolong survival, decrease organ fungal burden, and reduce serum polysaccharide antigen. In vitro experiments suggest that protective mAbs modify the course of infection by enhancing effector cell function against C. neoformans. Addition of mAb to antifungal drugs enhances their efficacy against C. neoformans in vivo and in vitro. Human-mouse chimeric antibodies with activity against C. neoformans have been constructed. A highly immunogenic capsular polysaccharide-protein vaccine has been synthesized that elicits protective antibodies in mice. Antibody immunity elicited by conjugate vaccines or provide by passive administration may be useful in the prevention treatment of human cryptococcal infections.

UR - http://www.scopus.com/inward/record.url?scp=0030221601&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030221601&partnerID=8YFLogxK

M3 - Article

VL - 284

SP - 475

EP - 495

JO - International Journal of Medical Microbiology

JF - International Journal of Medical Microbiology

SN - 1438-4221

IS - 4

ER -